Alpha Biopharma
Alpha Biopharma is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Shanghai, China, with an additional office in Beijing. The company focuses on the clinical development and commercialization of global innovative drugs across oncology and immunotherapy, spanning medical affairs, clinical operations, regulatory affairs and commercialization. Its lead product is Zorifertinib (formerly AZD-3759, marketed as Zorifer), a next-generation EGFR TKI designed for EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which received NMPA approval in November 2024 as the first EGFR-TKI indicated for lung cancer with brain metastases. Alpha Biopharma also partners with Wugen Inc. on universal off-the-shelf memory NK and CAR-T cell therapies. The company raised a Series A led by Qiming Venture Partners. Alpha Biopharma publishes a corporate marketing website only and operates no public API, developer portal, or software platform.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Alpha Biopharma the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Alpha Biopharma scores 8.1/100 (minimal), with a separate agent-readiness read of 4/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Alpha Biopharma
Each block below is one kind of artifact we hold for Alpha Biopharma. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Alpha Biopharma — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 6
The organization behind the API
Other 6
Properties that don't map to a standard resource type
← All providers · Data indexed from github.com/api-evangelist/alphabiopharma · machine-readable index on apis.io